(Q44505930)

English

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

scientific article published in January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline (English)

1 reference

Europe PubMed Central

3 December 2017

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Roberto Walter Dal Negro

1

1 reference

Europe PubMed Central

3 December 2017

Carlo Pomari

2

1 reference

Europe PubMed Central

3 December 2017

Silvia Tognella

3

1 reference

Europe PubMed Central

3 December 2017

Claudio Micheletto

4

1 reference

Europe PubMed Central

3 December 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

3 December 2017

Pulmonary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

3 December 2017

16

1 reference

Europe PubMed Central

3 December 2017

4

1 reference

Europe PubMed Central

3 December 2017

241-246

1 reference

Europe PubMed Central

3 December 2017

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol plus theophylline combination therapy in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of inhaled corticosteroids in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900065-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1094-5539(03)00065-8

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44505930&oldid=2025935619"